How “Stocking the Pantry” Protects the Supply Chain
AAM’s Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain and documents like it provide lawmakers with the ingredients for achieving a legislative goal.
Strengthening the U.S. Pharmaceutical Supply Chain: What We Know—and What We Don’t
Last week the U.S. Department of Health and Human Services announced a grant worth up to $812 million for a public-private partnership to manufacture COVID-related medicines in the United States.
AAM Statement on Senate Finance Hearing on FDA’s Foreign Manufacturing Inspection Process
WASHINGTON, DC (June 2, 2020) — The COVID-19 crisis exposed many shortcomings in our health care system’s ability to respond to a pandemic. At the same time, many parts of that same system — including the supply chain for the vast majority of generic medicines — demonstrated extraordinary resiliency in the face of unprecedented stresses.
COVID Response: Sweta Modha at Apotex
Sweta Modha works as a Packaging Technician at Apotex. AAM is recognizing dedicated people like Sweta who show up each day for America's patients. She is proud to work to ensure the supply chain continuity of essential medicines during the #COVID19 public health emergency.
COVID Response: AAM Board Chair Alok Sonig
AAM Board Chair Alok Sonig at Lupin: "We are working night and day globally across our manufacturing footprint to make sure our essential employees are able to come to our sites... and despite the challenges are able to make the product that is critically needed globally and we are doing that." #covid19
AAM’s Plan for Strengthening the Generic Drug Supply Chain
The COVID-19 (Coronavirus) pandemic is reminding all of us how much health matters in our families, our communities and our nation. The Association for Accessible Medicines is committed to the secure and consistent supply of critical pharmaceuticals that support good health and the recharging of the U.S. economy.
Pharmaceutical Shipping Costs Spike in Response to Global COVID-19 Pandemic
AAM Survey of Biosimilars and Generic Drug Manufacturers Reveals Average of 224% Increase In Cost of Transporting Drugs
A Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain
Introduction
A closely connected, diverse and resilient pharmaceutical supply chain based in the United States and in U.S. allied countries (for example, Canada, Europe, India, Israel and Jordan) is the best means to ensure that U.S. patients and the U.S. health care system have access to a secure and consistent supply of critical pharmaceuticals.
AAM Releases Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain
WASHINGTON, DC (April 30, 2020) — The Association for Accessible Medicines today released “A Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain,” a six-element framework that lays out concrete actions that the federal government could take to ensure that U.S. patients and the U.S. health care system have access to a secure and consistent supply of critical pharmaceuticals.
COVID-19 Response: Anthony Maffia at Sandoz
Anthony Maffia works in New Jersey at Sandoz as Vice President, Head of Regulatory Affairs, North America.
AAM is recognizing dedicated people like Anthony and his peers across the generic & biosimilar industry who show up each day for US patients.
The industry is "finding new and creative and rapid ways to get medication into the hands of patients that need it.”